Moleculin Biotech
Moleculin is a Houston biotech whose annamycin, an anthracycline designed to spare the heart, is in a phase 3 trial with cytarabine for relapsed acute myeloid leukaemia.
Overview
Moleculin Biotech, headquartered in Houston, Texas, licenses drug candidates from MD Anderson Cancer Center. Its lead, annamycin, is a liposomal anthracycline engineered to avoid the cardiotoxicity of doxorubicin and to evade multidrug resistance pumps, and is in the phase 3 MIRACLE trial with cytarabine in relapsed or refractory acute myeloid leukaemia; WP1066, a STAT3 inhibitor, is in earlier trials in brain tumours. Its trials are registered on ClinicalTrials.gov under Moleculin as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyDiffusion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanySunesis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyVion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyDelta-Fly Pharma
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.